Fischer Medical Ventures Ltd (FMV), through its associate company Nanyang Biologics (NYB), has announced a landmark collaboration with global technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to co-develop VECURA, an AI-powered drug discovery platform. This breakthrough initiative combines advanced predictive models with a proprietary library of millions of natural compounds to accelerate the development of next-generation health solutions.

Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours. Anchored in Singapore, this collaboration with NVIDIA, HPE, and Equinix is set to build the world’s largest AI-curated compound library, leveraging cutting-edge computing, cloud infrastructure, and AI-driven insights.

NYB’s VECURA harnesses artificial intelligence, machine learning, and virtual screening to revolutionize traditional drug discovery, which is often slow, costly, and inefficient. By curating a vast natural compound library derived from tropical flora and integrating advanced metagenomics and metaproteomics analysis, VECURA can rapidly identify promising drug candidates. This innovation significantly reduces discovery time and costs, opening new frontiers in personalized medicine and nature-based therapeutics.

Beyond drug discovery, NYB is also applying its platform to create evidence-based nutraceuticals aimed at enhancing human resilience, restoring metabolic balance, and promoting longevity. At the forefront of this effort is CareViva NS, a scientifically validated formulation derived from traditional herbs, developed in collaboration with over 26 scientists and professors from Nanyang Technological University, Singapore. FMV will serve as NYB’s global distribution partner, leveraging its extensive network to make these next-generation nutraceuticals accessible worldwide.